S&P 500   3,699.12 (+0.88%)
DOW   30,218.26 (+0.83%)
QQQ   305.52 (+0.41%)
AAPL   122.25 (-0.56%)
MSFT   214.36 (+0.06%)
FB   279.70 (-0.76%)
GOOGL   1,823.76 (+0.11%)
AMZN   3,162.58 (-0.76%)
TSLA   599.04 (+0.95%)
NVDA   542.33 (+1.21%)
BABA   267.25 (+0.13%)
CGC   28.59 (-0.14%)
GE   10.88 (+2.64%)
MU   73.34 (+4.92%)
AMD   94.04 (+1.87%)
T   29.54 (+1.06%)
NIO   43.04 (-5.09%)
F   9.34 (+1.41%)
ACB   10.89 (-3.11%)
BA   232.71 (-1.89%)
NFLX   498.31 (+0.16%)
GILD   61.56 (+1.15%)
DIS   154.14 (+0.59%)
S&P 500   3,699.12 (+0.88%)
DOW   30,218.26 (+0.83%)
QQQ   305.52 (+0.41%)
AAPL   122.25 (-0.56%)
MSFT   214.36 (+0.06%)
FB   279.70 (-0.76%)
GOOGL   1,823.76 (+0.11%)
AMZN   3,162.58 (-0.76%)
TSLA   599.04 (+0.95%)
NVDA   542.33 (+1.21%)
BABA   267.25 (+0.13%)
CGC   28.59 (-0.14%)
GE   10.88 (+2.64%)
MU   73.34 (+4.92%)
AMD   94.04 (+1.87%)
T   29.54 (+1.06%)
NIO   43.04 (-5.09%)
F   9.34 (+1.41%)
ACB   10.89 (-3.11%)
BA   232.71 (-1.89%)
NFLX   498.31 (+0.16%)
GILD   61.56 (+1.15%)
DIS   154.14 (+0.59%)
S&P 500   3,699.12 (+0.88%)
DOW   30,218.26 (+0.83%)
QQQ   305.52 (+0.41%)
AAPL   122.25 (-0.56%)
MSFT   214.36 (+0.06%)
FB   279.70 (-0.76%)
GOOGL   1,823.76 (+0.11%)
AMZN   3,162.58 (-0.76%)
TSLA   599.04 (+0.95%)
NVDA   542.33 (+1.21%)
BABA   267.25 (+0.13%)
CGC   28.59 (-0.14%)
GE   10.88 (+2.64%)
MU   73.34 (+4.92%)
AMD   94.04 (+1.87%)
T   29.54 (+1.06%)
NIO   43.04 (-5.09%)
F   9.34 (+1.41%)
ACB   10.89 (-3.11%)
BA   232.71 (-1.89%)
NFLX   498.31 (+0.16%)
GILD   61.56 (+1.15%)
DIS   154.14 (+0.59%)
S&P 500   3,699.12 (+0.88%)
DOW   30,218.26 (+0.83%)
QQQ   305.52 (+0.41%)
AAPL   122.25 (-0.56%)
MSFT   214.36 (+0.06%)
FB   279.70 (-0.76%)
GOOGL   1,823.76 (+0.11%)
AMZN   3,162.58 (-0.76%)
TSLA   599.04 (+0.95%)
NVDA   542.33 (+1.21%)
BABA   267.25 (+0.13%)
CGC   28.59 (-0.14%)
GE   10.88 (+2.64%)
MU   73.34 (+4.92%)
AMD   94.04 (+1.87%)
T   29.54 (+1.06%)
NIO   43.04 (-5.09%)
F   9.34 (+1.41%)
ACB   10.89 (-3.11%)
BA   232.71 (-1.89%)
NFLX   498.31 (+0.16%)
GILD   61.56 (+1.15%)
DIS   154.14 (+0.59%)
Log in
NASDAQ:PRAX

Praxis Precision Medicines Stock Forecast, Price & News

$43.40
+1.44 (+3.43 %)
(As of 12/4/2020 12:00 AM ET)
Add
Today's Range
$41.13
Now: $43.40
$43.97
50-Day Range N/A
52-Week Range
$23.90
Now: $43.40
$46.71
Volume151,744 shs
Average Volume257,334 shs
Market Capitalization$1.66 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement Purdue Neuroscience Company; and a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc. The company was incorporated in 2015 and is based in Cambridge, Massachusetts.

Beat the Market (BTM) Rank

Analyst Opinion: 2.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.83 out of 5 stars


Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolNASDAQ:PRAX
CUSIPN/A
CIKN/A
Phone617-300-8460
Employees37

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Market Cap$1.66 billion
Next Earnings DateN/A
OptionableNot Optionable
$43.40
+1.44 (+3.43 %)
(As of 12/4/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PRAX News and Ratings via Email

Sign-up to receive the latest news and ratings for PRAX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Praxis Precision Medicines (NASDAQ:PRAX) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Praxis Precision Medicines?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Praxis Precision Medicines in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Praxis Precision Medicines
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Praxis Precision Medicines?

Wall Street analysts have given Praxis Precision Medicines a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Praxis Precision Medicines wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were Praxis Precision Medicines' earnings last quarter?

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) announced its earnings results on Sunday, November, 22nd. The company reported ($12.10) EPS for the quarter, missing the consensus estimate of ($0.73) by $11.37.
View Praxis Precision Medicines' earnings history
.

What price target have analysts set for PRAX?

4 analysts have issued 12 month price targets for Praxis Precision Medicines' stock. Their forecasts range from $40.00 to $65.00. On average, they anticipate Praxis Precision Medicines' share price to reach $53.33 in the next year. This suggests a possible upside of 22.9% from the stock's current price.
View analysts' price targets for Praxis Precision Medicines
.

Who are Praxis Precision Medicines' key executives?

Praxis Precision Medicines' management team includes the following people:
  • Dr. Kiran Reddy M.D., Co-Founder & Director (Age 43, Pay $576.59k)
  • Dr. Stuart Chaffee Ph.D., Chief Financial Officer (Age 47, Pay $391.77k)
  • Dr. Bernard Ravina, Chief Medical Officer (Age 53, Pay $551.27k)
  • Mr. Marcio Souza, Pres, CEO & Director (Age 41)
  • Dr. David B. Goldstein Ph.D., Co-Founder
  • Dr. Steven Petrou, Co-Founder & Chief Scientific Officer
  • Lauren Mastrocola, Principal Accounting Officer
  • Mr. Alex Nemiroff J.D., Gen. Counsel & Sec. (Age 41)
  • Mr. Karl Hansen, Sr. VP of CMC
  • Ms. Nicole Sweeny, Chief Commercial Officer (Age 45)

When did Praxis Precision Medicines IPO?

(PRAX) raised $126 million in an IPO on Friday, October 16th 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. Cowen, Evercore ISI, Piper Sandler and Wedbush PacGrow acted as the underwriters for the IPO and Blackstone Capital Markets was co-manager.

What is Praxis Precision Medicines' stock symbol?

Praxis Precision Medicines trades on the NASDAQ under the ticker symbol "PRAX."

When did the company's quiet period expire?

Praxis Precision Medicines' quiet period expired on Wednesday, November 25th. Praxis Precision Medicines had issued 10,000,000 shares in its IPO on October 16th. The total size of the offering was $190,000,000 based on an initial share price of $19.00. During the company's quiet period, underwriters and any insiders involved in the IPO were restricted from issuing any earnings forecasts or research reports for the company because of SEC regulations. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

How do I buy shares of Praxis Precision Medicines?

Shares of PRAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Praxis Precision Medicines' stock price today?

One share of PRAX stock can currently be purchased for approximately $43.40.

How big of a company is Praxis Precision Medicines?

Praxis Precision Medicines has a market capitalization of $1.66 billion. Praxis Precision Medicines employs 37 workers across the globe.

What is Praxis Precision Medicines' official website?

The official website for Praxis Precision Medicines is www.praxismedicines.com.

How can I contact Praxis Precision Medicines?

The company can be reached via phone at 617-300-8460.

This page was last updated on 12/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.